Ascension's Clinical Symposium 2024- NicoTEENs and Evidence-Based Treatments for Nicotine Use Disorders

---

ONLINEABSCCMOC

Pop-up Blockers

Monday, November 4, 2024, 1:00 AM - Wednesday, November 4, 2026, 11:59 PM


AMA PRA Category 1 Credits™ (0.50 hours), AAPA Credit(s) (0.50 hours), ABS CC (0.50 hours), ACPE Contact Hour(s) (0.50 hours), ANCC Contact Hour(s) (0.50 hours), ASWB Credit(s) (0.50 hours), General Attendance (0.50 hours), IPCE Credit(s) (0.50 hours), Non-Physician Attendance (0.50 hours)

Ascension continues to accelerate our transformation to an integrated health ministry that delivers improved health outcomes for the individuals and communities we serve, ensuring quality and safety is a differentiator will be key. To that end, we are excited to announce the Ascension Clinical Symposium 2024.

1. Define addiction (including nicotine use disorders) as a chronic brain disease.
2. Develop and understand of the pharmacological and non-pharmacological treatment options for nicotine use disorders.

This activity was planned by and for the healthcare team, and learners will receive 0.50 IPCE credits for learning and change.

Cancellation Policy

Cancellations received in writing no less than 20 days before the course will be refunded, less a 20% administrative fee. No refunds will be made on cancellations received after that date. Please send cancellation requests to [email protected]

Ascension reserves the right to cancel or postpone this program if necessary; in the event of cancellation, course fees will be fully refunded.

Ascension adheres to ACCME Criteria, Standards and Policies regarding industry support of CE/CME. Disclosure of faculty and their commercial relationships will be made prior to the activity.

Mitigation of Relevant Financial Relationships

Ascension adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

No commercial interest was received for this CE/CME activity.